A PHASE 1, RANDOMIZED, 2-WAY CROSSOVER, SINGLE DOSE, OPEN LABEL STUDY TO ESTIMATE THE EFFECT OF PF-04965842 ON DABIGATRAN PHARMACOKINETICS IN HEALTHY PARTICIPANTS
Phase of Trial: Phase I
Latest Information Update: 19 Mar 2019
Price : $35 *
At a glance
- Drugs Abrocitinib (Primary) ; Dabigatran etexilate
- Indications Atopic dermatitis
- Focus Pharmacokinetics
- Sponsors Pfizer
- 14 Mar 2019 Status changed from recruiting to completed.
- 19 Dec 2018 Status changed from not yet recruiting to recruiting.
- 03 Dec 2018 Planned initiation date changed from 1 Nov 2018 to 1 Dec 2018.